Lip, Gregory Y HGregory Y HLipKotalczyk, AgnieszkaAgnieszkaKotalczykTeutsch, ChristineChristineTeutschDiener, Hans-ChristophHans-ChristophDienerDubner, Sergio JSergio JDubnerHalperin, Jonathan LJonathan LHalperinMa, Chang-ShengChang-ShengMaRothman, Kenneth JKenneth JRothmanMarler, SabrinaSabrinaMarlerGurusamy, Venkatesh KumarVenkatesh KumarGurusamyFU-TIEN CHIANGHuisman, Menno VMenno VHuisman2022-05-112022-05-112022-051861-0684https://scholars.lib.ntu.edu.tw/handle/123456789/610418Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF).enApixaban; Atrial fibrillation; Dabigatran; Non-vitamin K antagonists; RivaroxabanComparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registryjournal article10.1007/s00392-022-01996-2352946252-s2.0-85126339162WOS:000769859700003https://api.elsevier.com/content/abstract/scopus_id/85126339162